Crohn's disease

in review 4 min read Updated 2026-10-28
Crohn’s disease

Transmural, skip-lesion inflammation anywhere from mouth to anus, most often terminal ileum. Progressive: most patients develop strictures or fistulae without effective control. Symptoms track inflammation poorly → treat to objective targets (calprotectin, endoscopy, imaging). Steroids induce, never maintain. 5-ASA has no role. Moderate–severe or high-risk disease → early advanced therapy, infliximab + thiopurine the strongest combination. Perianal fistula → drain sepsis first, then infliximab ± thiopurine; antibiotics as adjuncts (alone only for simple fistulae). Abscess >2 cm → drain before immunosuppression.

who needs early advanced therapy

Failure of conventional therapy is not a prerequisite for advanced therapy.

High-risk features (any → advanced therapy early):

  • young age at diagnosis
  • extensive bowel involvement; ileal/ileocolonic or upper GI disease
  • perianal or severe rectal disease
  • deep ulcers on colonoscopy
  • stricturing or penetrating phenotype at diagnosis
  • extraintestinal manifestations at diagnosis

PROFILE (2024): newly diagnosed active CD, infliximab + immunomodulator from the start vs accelerated step-up → sustained steroid- and surgery-free remission 79% vs 15% at 1 year, fewer surgeries. Open-label, but large effect.

Low-risk, mild disease (short ileal segment, older, no high-risk features) → budesonide induction, then monitor objectively. Untreated observation acceptable for mild asymptomatic disease with surveillance.

induction and maintenance

severity / siteinductionmaintenance
mild–moderate ileocaecalbudesonide 9 mg daily (ileal release)none, or advanced therapy if relapses; budesonide doesn’t maintain
mild colonicsulfasalazine (only 5-ASA with any colonic signal)—
moderate–severeprednisone 40–60 mg/day; assess at 2–4 weeksadvanced therapy; thiopurine or SC/IM methotrexate after steroid induction
severe, hospitalisedIV methylprednisolone 40–60 mg/day; assess within 1 week; infliximab inpatient if severe—
  • Oral 5-ASA: against for induction and maintenance of CD.
  • Systemic antibiotics don’t treat luminal inflammation.
  • Thiopurines alone don’t induce (slow onset ~3 months) — useful for maintenance after steroids and to reduce anti-drug antibodies with anti-TNF.
  • TPMT (± NUDT15) before azathioprine — deficiency → myelosuppression.
  • Steroid dependence or resistance → advanced therapy, not repeated courses.

choosing an advanced therapy

All are recommended for moderate–severe CD. General choice (infection risk, loss of response, biosimilars), screening and toxicities → IBD advanced therapies. CD-specific points:

situationpreferred
biologic-naive, high risk, perianal diseaseinfliximab + thiopurine (SONIC (2010): steroid-free remission at 26 wk 57% combination vs 44% infliximab vs 30% azathioprine)
prior anti-TNF failurerisankizumab over ustekinumab (conditional, low evidence); upadacitinib
active spondyloarthritisanti-TNF

perianal fistulising disease

  1. MRI pelvis (or EUS) ± examination under anaesthesia to map fistula and abscess.
  2. Drain abscesses and place setons first — advanced therapy on undrained sepsis → abscess.
  3. Infliximab (± thiopurine) is first-line; adalimumab an alternative. Vedolizumab, ustekinumab and upadacitinib have weaker data.
  4. Ciprofloxacin/metronidazole improve response when added to anti-TNF; alone they’re acceptable only for simple fistulae, and relapse on stopping.
perianal CD

Antibiotics are an adjunct, not the treatment — complex perianal fistula needs anti-TNF after surgical drainage.

complications

Intra-abdominal abscess → CT or MR → abscess >2 cm: antibiotics + percutaneous or surgical drainage; hold immunosuppression until drained. Most eventually need resection of the diseased segment.

Stricture — distinguish inflammatory from fibrotic by imaging and endoscopy:

  • active inflammation (enhancement, ulceration, raised CRP) → advanced therapy
  • fibrostenotic, short segment → endoscopic balloon dilation; long or multiple → resection or strictureplasty

Bowel obstruction, perforation, refractory bleeding, dysplasia/cancer → surgery.

Ileal resection → bile acid diarrhoea (bile acid sequestrant); >100 cm resected → fat malabsorption and steatorrhoea instead; B12 deficiency (chronic diarrhoea).

after surgery

Endoscopic recurrence in ~50% within 1–3 years; symptomatic recurrence ~50% at 5 years.

riskapproach
low (non-smoker, no penetrating disease, first resection)no treatment; colonoscopy at 6–12 months
intermediate (penetrating, first resection)thiopurine ± metronidazole; colonoscopy at 6 months
high (prior resection, smoker)anti-TNF ± immunomodulator (vedolizumab alternative)

Rutgeerts ≥i2b at 6-month colonoscopy → escalate.

monitoring and long-term care

  • Targets: symptom remission + normal CRP and calprotectin + endoscopic healing. Calprotectin above ~50–100 µg/g (assay-dependent) separates inflammatory from functional symptoms.
  • Stool culture and C. difficile (clostridioides difficile infection) with every flare.
  • Smoking cessation — smoking worsens CD (opposite of UC) and accelerates post-operative recurrence.
  • NSAIDs can trigger flares — avoid routine use.
  • CRC surveillance colonoscopy for Crohn’s colitis involving >30% of the colon, from 8 years after diagnosis; PSC → from diagnosis regardless of extent (ulcerative colitis); a first-degree relative with CRC adds risk (cancer screening — Canadian guidelines).
  • Bone health (steroids, malabsorption), iron, B12, vitamin D; depression and anxiety screening.
  • Vaccines and pre-therapy screening → IBD advanced therapies.

distinguishing CD from UC

Crohn’sUC
distributionskip lesions, mouth to anus; terminal ileum most oftencontinuous from rectum
depthtransmural → fistula, stricture, abscessmucosal
rectumoften sparedalways involved
perianal diseasecommonno
histologynon-caseating granulomas (minority)crypt abscesses, no granulomas
smokingworsensprotective

Prepared 2026-10-28. Not yet verified — check every number against the sources.

Key references

+1 more source

Suggest a correction Crohn's disease